MYELOMA-HCQ: Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma

Sponsor

Norwegian University of Science and Technology (Other)

Overall Status

Completed

CT.gov ID

NCT04163107

Collaborator

St. Olavs Hospital (Other), Oslo University Hospital (Other)

Enrollment

Locations

Arm

23.7

Actual Duration (Months)

9.5

Patients Per Site

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Multiple myeloma (MM) is a neoplastic expansion of bone marrow plasma cells. Despite advances in treatment in recent years, MM is still a fatal disease. MM is characterized by the ability of malignant cells to produce large amounts of monoclonal immunoglobulin. The secretion of these immunoglobulins can be detected as the "M-protein" in serum, and the measurement of the M-component is used both for diagnosis and to evaluate treatment response and relapse. The high load of secreted proteins in MM cells requires a efficient way to clear these proteins from the cells and targeting protein degradation is an important therapeutic target in MM. This is today done by inhibiting the proteasome, one of the two central ways cells can degrade proteins, by drugs named proteasome inhibitors (including bortezomib, ixazomib and carfilzomib). Patients become resistant to these drugs, and it is therefore likely that myeloma cells also utilise another important system for protein degradation, called autophagy. Pre-clinical studies have shown that the combination of the proteasome inhibitor carfilzomib and the autophagy inhibitor hydroxychloroquine increases myeloma cell death and that hydroxychloroquine is able to reverse MM cell resistance to carfilzomib. This is the rationale for this study, where the investigators add the autophagy inhibitor hydroxychloroquine to a standard regime of carfilzomib and dexamethasone, to determine a maximum tolerated dose of this combination and to study tolerability.

Condition or Disease	Intervention/Treatment	Phase
Multiple Myeloma	Drug: Hydroxychloroquine Drug: Carfilzomib Injection Drug: Dexamethasone	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

19 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

A single arm, dose escalation study in two centers. 3+3 design in five dose levels.A single arm, dose escalation study in two centers. 3+3 design in five dose levels.

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma - a Phase 1 Trial

Actual Study Start Date :

Jan 7, 2020

Actual Primary Completion Date :

Dec 28, 2021

Actual Study Completion Date :

Dec 28, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Combination treatment of carfilzomib/dexamethasone/HCQ	Drug: Hydroxychloroquine All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level. Drug: Carfilzomib Injection All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level. Drug: Dexamethasone All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.

Arm

Intervention/Treatment

Experimental: Combination treatment of carfilzomib/dexamethasone/HCQ

Drug: Hydroxychloroquine

All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.

Drug: Carfilzomib Injection

Drug: Dexamethasone

Outcome Measures

Primary Outcome Measures

maximum tolerated dose of hydroxychloroquine when added to standard-dose regimen of carfilzomib/dexamethasone [3 months]

Secondary Outcome Measures

estimate of toxicity rate of hydroxychloroquine when added at a maximum tolerated dose to standard-dose regimen of carfilzomib/dexamethasone [3 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Demographic and diagnosis

A prior diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) criteria with documented disease progression in need of treatment at time of screening.
Must meet all of the following criteria:
Patients must have received at least two prior therapies including bortezomib and an immunomodulatory agent (may include autologous bone marrow transplantation)
Patients must not be refractory to carfilzomib
Relapsed or progressive disease documented according to IMWG criteria
Patients must have evaluable multiple myeloma with at least one of the following (assessed within 21 days prior to registration)
Serum M-protein ≥ 10 g/L, or
Urine M-protein ≥ 200 mg/24 hours
Involved serum immunoglobulin free light chain (SFLC) > 100 mg/L AND abnormal kappa/lambda ratio
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Life expectancy ≥ 6 months

Laboratory:

Absolute neutrophil count ≥ 1.0 x 109/L
Hemoglobin ≥ 7 g/dL (with or without transfusion support)
Platelets ≥ 50 x 109/L (with or without transfusion support)
Total bilirubin ≤ 2 x upper limit of normal (ULN)
Aspartate amino transferase/alanine amino transferase ratio (ASAT/ALAT) ≤ 2.5 x ULN
Creatinine ≤ 2 x ULN

Concurrent conditions

Left ventricular ejection fraction (LVEF) ≥ 40 % determined by 2D transthoracic echocardiogram (ECHO) or Multigated Acquisition Scan (MUGA)
No baseline peripheral neuropathy ≥ grade 2
No history of allergic reactions to compounds of similar chemical or biological composition to carfilzomib, dexamethasone or hydroxychloroquine, including Captisol (a cyclodextrin derivate used to solubilize carfilzomib)
No macular degeneration or retinopathy (diabetic or otherwise) as examined during screening, or known porphyria or psoriasis (with the exception of early dry age-related macular degeneration or minor microhemorrhages in the retinal periphery)
Well-controlled psoriasis allowed under care of a specialist who agrees to monitor the patient for exacerbations
No other condition that would require therapy with hydroxychloroquine, including but not limited to, any of the following:
Systemic lupus erythematosus
Rheumatoid arthritis
Porphyria cutanea tarda
Malaria treatment or prophylaxis
No concurrent or prior malignancy except for the following:
Basal cell or squamous cell carcinoma of the skin
Treated carcinoma in situ
Localized prostate adenocarcinoma (stage T1a or T1b) with a stable prostate-specific antigen (PSA) for a period fo at least 4 months allowed
Patients with a prior malignancy treated with chemotherapy, biologic agents, and/or radiation are eligible for this study if they have completed therapy ≥ 2 years previously with no evidence of recurrent disease
Patients with a prior malignancy treated with surgery alone are eligible for this study if they have completed therapy ≥ 2 years previously with no evidence of recurrent disease
No uncontrolled intercurrent illness including, but not limited to, any of the following:
Uncontrolled ongoing infection
Known acute or chronic hepatitis B, active hepatitis A or C or human immunodeficiency virus (HIV)
Symptomatic congestive heart failure, defined as New York Heart Association (NYHA) Class III or IV
Unstable angina pectoris
Myocardial infarction within 6 months of enrollment
Cardiac arrhythmia
Clinically significant pericardial disease
Cardiac amyloidosis
Severe lung disease
Psychiatric illness or social situations that would prevent compliance with study requirements

Prior and concurrent therapy

No prior dose reductions of carfilzomib administration in previous lines
At least 14 days since prior antimyeloma agents, not including carfilzomib/dexamethasone
Concurrent therapy with bisphosphonates allowed at the discretion of the treating physician
Concurrent hematopoetic growth factors allowed, including filgrastim granulocyte colony-stimulating factor (G-CSF) or pegfilgrastim, epoetin alpha, and darbepoetin alpha
Concurrent participation in non-treatment studies allowed, if it will not interfere with participation in this study
No concurrent radiotherapy except local radiotherapy during the treatment phase of this study for palliation of pain or prevention of fracture
No concurrent treatment with a different investigational regimen
No concurrent treatment with other anticancer agents
No concurrent participation in other investigational trials that involve novel therapies

Ethical/other

Female patients of child-bearing potential (FCBP) must have negative serum pregnancy test within 21 days prior to registration and agree to use an effective method of contraception during and for 3 months following last dose of drug.
Male patients must use an effective barrier method of contraception during study and for 3 months following the last dose if sexually active with a FCBP.
Ability to understand and willingness to sign the informed consent document
Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP), and national/local regulations.

Exclusion Criteria:

Not meeting inclusion criteria
Female patients who are pregnant or lactating.
Any reason why, in the opinion of the investigator, the patient should not participate (e.g. not able to comply with study procedures, including being unable to perform full ophthalmologic examination).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Oslo University Hospital, Department of Hematology, Oslo Myeloma Center	Oslo		Norway
2	St. Olavs Hospital, Department of Hematology	Trondheim		Norway

Sponsors and Collaborators

Norwegian University of Science and Technology
St. Olavs Hospital
Oslo University Hospital

Investigators

Study Director: Torstein Baade Rø, NTNU Department of Clinical and Molecular Medicine (IKOM)
Principal Investigator: Tobias S Slørdahl, MD PhD, Norwegian University of Science and Technology